Barclays Initiates Coverage On Intellia Therapeutics with Underweight Rating, Announces Price Target of $8

Benzinga · 2d ago
Barclays analyst Gena Wang initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Underweight rating and announces Price Target of $8.